Suppr超能文献

基于真实世界证据的造影剂临床安全性评价。

Clinical safety evaluation of contrast agents based on real-world evidence.

机构信息

Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou, China.

Endoscopy Center, Wenling Hospital of Traditional Chinese Medicine Affiliated to Zhejiang University of Traditional Chinese Medicine, Wenling, China.

出版信息

J Clin Pharm Ther. 2021 Dec;46(6):1600-1605. doi: 10.1111/jcpt.13485. Epub 2021 Jul 22.

Abstract

WHAT IS KNOWN AND OBJECTIVE

This study was aimed at comparing the adverse drug reactions (ADRs) arising from the use of iodinated contrast medium (ICM) and gadolinium-based contrast media (GBCM), and to provide a basis for the clinical selection of contrast media.

METHODS

Retrospective data for ADR cases occurring from the use of ICM or GBCM during enhanced scanning in computed tomography and magnetic resonance imaging were collected between June/2013 and May/2020 from Wenling Hospital of Traditional Chinese Medicine. Chi-square tests were performed based on the characteristics of patients and the classification of contrast medium. Bonferroni correction was applied to the statistical analyses with multiple comparisons of proportions.

RESULTS

Among 27,328 patients who were subjected to enhanced CT scanning, 207 cases (0.76%) showed ICM-related ADRs. Among 16,381 patients who were subjected to enhanced MRI scanning, 25 cases (0.15%) showed ADRs related to GBCM. The incidence of ADR induced by GBCM was significantly lower than ICM-induced ADR (p < 0.01). There were no significant differences in the incidence among different types of ICM, including ioversol and iodixanol, as well as iodixanol from different manufacturers (p > 0.05). Interestingly, the ADR incidence of ICM seemed to be associated with gender, with a significantly higher incidence in females than in male patients, and it was also associated with the age, with a lower occurrence in older (>44 years) compared to younger patients.

WHAT IS NEW AND CONCLUSION

With respect to ADR incidence, the safety profile of ICM of different types and different manufacturers was found to be similar in clinical use, warranting no need of specifically choosing imported or more expensive products. While choosing contrast medium type for clinical use, attention should be paid to certain populations, especially to younger and female patients when the patients are about to undergo a contrast-enhanced examination.

摘要

已知和目的

本研究旨在比较碘对比剂(ICM)和钆基对比剂(GBCM)使用引起的不良反应(ADR),为临床选择对比剂提供依据。

方法

回顾性收集 2013 年 6 月至 2020 年 5 月温岭市中医院行增强 CT 及磁共振成像检查时使用 ICM 或 GBCM 后发生的 ADR 病例资料。根据患者特征和对比剂分类进行卡方检验,对多个比例的统计分析进行了 Bonferroni 校正。

结果

在 27328 例接受增强 CT 扫描的患者中,207 例(0.76%)出现与 ICM 相关的 ADR。在 16381 例接受增强 MRI 扫描的患者中,25 例(0.15%)出现与 GBCM 相关的 ADR。GBCM 引起的 ADR 发生率明显低于 ICM 引起的 ADR(p<0.01)。不同类型的 ICM(包括碘海醇和碘佛醇,以及不同制造商的碘佛醇)之间的发生率无显著差异(p>0.05)。有趣的是,ICM 的 ADR 发生率似乎与性别有关,女性明显高于男性,也与年龄有关,年龄较大(>44 岁)的患者发生率较低。

新内容和结论

在不良反应发生率方面,不同类型和不同制造商的 ICM 在临床使用中的安全性特征相似,无需特别选择进口或更昂贵的产品。在选择临床使用的对比剂类型时,应注意某些人群,特别是在进行增强检查时,应注意年轻和女性患者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验